Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Webinar | Special Topics Related to Obviousness in the Context of Drug Development

Tuesday, June 23rd, 2020, 1:30 pm EDT

Webinar | Special Topics Related to Obviousness in the Context of Drug Development

This webinar took place on: Tuesday, June 23rd, 2020, 1:30 pm EDT

This webinar has ended.

Obviousness is the most common rejection basis during patent prosecution and one of the most common challenges in patent litigation and post-grant proceedings. When faced with a prima facie case of obviousness during prosecution, the burden is on the applicant to prove the invention’s nonobviousness — an often challenging task. In the pharmaceutical industry, companies would be well-served by keeping potential obviousness challenges in mind throughout the drug development process.

In this webinar, Fish attorneys Teresa Lavoie and Angela Follett discuss strategic portfolio and exclusivity calculation considerations related to obviousness in the development of drugs, including:

  • Repurposing of previously approved drugs
  • New uses for abandoned drug candidates
  • The impact of clinical trial disclosures
  • The intersection of PTA, PTE, and obviousness-type double-patenting.

Click the link to download a copy of the webinar slides.

Presenters: Angela Follett, Teresa Lavoie

Related Services
Related Industries
Related Offices